Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) granted stock options and restricted stock units to new hires on November 16, 2026. The awards, made under Nasdaq Listing Rule 5635(c)(4), include options to buy 225,000 common shares and 9,000 restricted stock units.
The options have a 10-year term and a $27.93 exercise price per share, equal to the common stock’s closing price on the grant date. Both awards vest over four years, subject to continued employment or other service through the applicable vesting dates. The awards are governed by the 2026 Inducement Plan and applicable award agreements.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options to buy 225,000 common shares at $27.93 per share could dilute existing holders if exercised.
- Minor point. Forward-looking: it has not happened yet and may not happen.9,000 restricted stock units could dilute existing holders as they vest and settle in common shares.
Key Figures
- Stock options granted
- 225,000 shares
- Inducement grants to newly hired employees
- RSUs granted
- 9,000 shares
- Inducement grants to newly hired employees
- Option exercise price
- $27.93 per share
- Equal to the closing price on the Grant Date
- Stock option term
- Ten years
- Term of the inducement stock options
- Stock option vesting
- Four-year period; 25% at the one-year anniversary, then 36 equal monthly installments
- Subject to continued employee service
- RSU vesting
- Four equal installments over a four-year period
- Subject to continued employee service
Historical Context
-
Prior employee inducement awards were 74,900 RSUs vesting in four equal annual installments.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 225,000 shares of the Company’s common stock (“Stock Options”) and an aggregate of 9,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Stock Options have a ten-year term and an exercise price per share of
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Contacts:
Investors:
Argot Partners
Zenas@argotpartners.com
Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.